4basebio PLC (AIM:4BB)

4basebio Statistics

Total Valuation

4basebio has a market cap or net worth of GBP 75.07 million. The enterprise value is 73.77 million.

Market Cap	75.07M
Enterprise Value	73.77M

Important Dates

The last earnings date was Friday, May 22, 2026.

Earnings Date	May 22, 2026
Ex-Dividend Date	n/a

Share Statistics

4basebio has 15.48 million shares outstanding. The number of shares has increased by 18.24% in one year.

Current Share Class	15.48M
Shares Outstanding	15.48M
Shares Change (YoY)	+18.24%
Shares Change (QoQ)	+0.27%
Owned by Insiders (%)	11.78%
Owned by Institutions (%)	40.84%
Float	5.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	44.34
PB Ratio	7.42
P/TBV Ratio	14.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.36
EV / Sales	43.57
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.60

Financial Position

The company has a current ratio of 7.31, with a Debt / Equity ratio of 1.63.

Current Ratio	7.31
Quick Ratio	6.40
Debt / Equity	1.63
Debt / EBITDA	n/a
Debt / FCF	-1.03
Interest Coverage	-19.84

Financial Efficiency

Return on equity (ROE) is -92.65% and return on invested capital (ROIC) is -32.25%.

Return on Equity (ROE)	-92.65%
Return on Assets (ROA)	-29.62%
Return on Invested Capital (ROIC)	-32.25%
Return on Capital Employed (ROCE)	-65.87%
Weighted Average Cost of Capital (WACC)	8.18%
Revenue Per Employee	15,391
Profits Per Employee	-153,682
Employee Count	110
Asset Turnover	0.05
Inventory Turnover	1.39

Taxes

Income Tax	-698,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.00% in the last 52 weeks. The beta is 0.87, so 4basebio's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	-60.00%
50-Day Moving Average	492.20
200-Day Moving Average	651.31
Relative Strength Index (RSI)	54.68
Average Volume (20 Days)	1,859

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, 4basebio had revenue of GBP 1.69 million and -16.91 million in losses. Loss per share was -1.09.

Revenue	1.69M
Gross Profit	974,000
Operating Income	-17.60M
Pretax Income	-17.60M
Net Income	-16.91M
EBITDA	-16.66M
EBIT	-17.60M
Loss Per Share	-1.09

Balance Sheet

The company has 17.80 million in cash and 16.51 million in debt, with a net cash position of 1.30 million or 0.08 per share.

Cash & Cash Equivalents	17.80M
Total Debt	16.51M
Net Cash	1.30M
Net Cash Per Share	0.08
Equity (Book Value)	10.11M
Book Value Per Share	0.65
Working Capital	17.84M

Cash Flow

In the last 12 months, operating cash flow was -15.59 million and capital expenditures -458,000, giving a free cash flow of -16.05 million.

Operating Cash Flow	-15.59M
Capital Expenditures	-458,000
Depreciation & Amortization	940,000
Net Borrowing	-400,000
Free Cash Flow	-16.05M
FCF Per Share	-1.04

Margins

Gross Margin	57.53%
Operating Margin	-1,039.57%
Pretax Margin	-1,039.75%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

4basebio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.24%
Shareholder Yield	-18.24%
Earnings Yield	-22.52%
FCF Yield	-21.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

4basebio has an Altman Z-Score of 0.43 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.43
Piotroski F-Score	1